secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2023-05-22T23:59:59+00:00
Accession:  0001711279-23-000039
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Krystal Biotech raises $160M in PIPE at $92.50/share for VYJUVEK launch and pipeline
--------------------------------------------------------------------------------

- Sold 1,729,729 shares at $92.50 each to institutional investors; gross proceeds ~$160M.
- PIPE led by Avoro Capital Advisors and Redmile Group, with Braidwell LP and Frazier Life Sciences.
- Proceeds to fund VYJUVEK commercialization, clinical pipeline, business development, and working capital.
- Company expects to fund operations through end of 2026; retains optionality on Priority Review Voucher.
- Registration statement for resale of shares to be filed within 60 days of closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127923000039/0001711279-23-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127923000039/krys-20230522.htm
  HTML page:      https://secwatch.observer/filing/0001711279-23-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer